ASX Runners of the Week: Ceretas, Pacgold & Hamelin Gold
The article links Middle East tensions to a jump in oil prices, with Brent up about 15% above US$100. It also cites Australia’s June employment gain of 76,300 and unemployment at 4.4%. ASX “runners” include Ceretas Ltd (CTS), up 142% after an $8m IPO for portable ultrasound in Alzheimer’s trials, and Pacgold Ltd (PGO), up 82% after high-grade copper-gold results at White Dam.
How this was made
The 30-second read
Why it matters
Ceretas’ IPO and early clinical safety plus Phase 2 initiation can sustain momentum trading, while Pacgold’s newly identified copper-gold system can drive speculative re-rating until assays and further drilling de-risk the resource potential.
Market read
Despite macro headwinds, the article spotlights fresh, tradable catalysts in ASX biotech and junior exploration, each tied to near-term execution milestones.
What to watch
The article does not quantify cash runway, dilution risk, or detailed assay verification timelines; those can dominate valuation after the initial headline surge.
Background
The piece frames a risk-off macro backdrop (oil up on Middle East tensions, stronger Australian jobs data delaying rate cuts) while highlighting two ASX “runners” with company-specific catalysts.
Ticker impact
Ceretas (CTS) is described as having surged 142% after its IPO, raising $8m to advance portable therapeutic ultrasound into Phase 2 for dementia symptoms.
Elevated volatility likely persists while investors price Phase 2 execution risk and early clinical read-through.
The article provides specific, time-relevant catalysts (IPO debut, $8m raised, Phase 1 safety in 12 patients, Phase 2 randomized double-blind study).
Market effects
Biotech and junior mining sentiment appears supported by concrete clinical and drill-result catalysts, even as macro and oil raise inflation fears.
Australia-focused risk appetite for ASX small caps, with attention on clinical trial execution (UQ spinout) and copper-gold exploration in South Australia.
Limited direct global linkage, though oil and Middle East disruption are cited as macro drivers that can affect discount rates and risk appetite.
Counterpoint
Large percentage moves in micro/small caps can reverse quickly if follow-up data (Phase 2 outcomes or assay confirmations) disappoints or takes longer than the market expects.
Key entities
- companyCeretas Ltd
Portable therapeutic focused-ultrasound platform; IPO raised $8m and Phase 2 CERE-CALM targets dementia behavioral and psychological symptoms.
- companyPacgold Ltd
White Dam gold project discovery of high-grade copper-gold beneath oxide gold; intercepts tied to a magnetic anomaly and more unassayed intervals.
